ProCE Banner Activity

Multiple Myeloma: Diagnosis and Treatment for 2023

PDF

Download this resource for useful point-of-care information including current multiple myeloma care algorithms, current drug approvals, clinical trial data , and adverse event identification.

Released: November 01, 2023

Share

Faculty

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Nikhil Munshi

Nikhil Munshi, MD

Professor of Medicine
Harvard Medical School
Kraft Family Chair
Director, Basic and Correlative Sciences & Associate Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Sanofi Genzyme and Takeda Pharmaceuticals U.S.A., Inc.

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Sanofi Genzyme

Takeda Pharmaceuticals U.S.A., Inc.

Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; independent contractor: TG Therapeutics.

Nikhil Munshi, MD

Professor of Medicine
Harvard Medical School
Kraft Family Chair
Director, Basic and Correlative Sciences & Associate Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Nikhil C. Munshi, MD: consultant/advisor/speaker: Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sebia; royalties or patent beneficiary: Oncopep.